EVP and General Counsel Michael Halstead Sells Shares of Intra-Cellular Therapies Inc
Michael Halstead, EVP and General Counsel of Intra-Cellular Therapies Inc (NASDAQ:ITCI), has sold 7,907 shares of the company on February 26, 2024, according to a recent SEC Filing. Over the past year, the insider has sold a total of 143,819 shares and has not made any purchases of the stock.
Intra-Cellular Therapies Inc is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of neuropsychiatric and neurological disorders. The company's product pipeline includes treatments for schizophrenia, depression, and other central nervous system disorders.
The insider transaction history for Intra-Cellular Therapies Inc shows a pattern of insider sales, with 29 insider sells and no insider buys over the past year.
On the date of the insider's recent sale, shares of Intra-Cellular Therapies Inc were trading at $69.53, giving the company a market cap of $7.057 billion.
The stock's price-to-GF-Value ratio stands at 0.35, with a GF Value of $196.13, indicating that Intra-Cellular Therapies Inc is categorized as a Possible Value Trap, Think Twice according to GuruFocus' valuation.
The GF Value is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
